Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Co-mutation signatures are age-dependent and impact the prognosis in <i>NPM1</i>-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Haematologica·2026

Same author

FEASIBILITY AND INTERIM SAFETY AND EFFICACY ANALYSIS OF A FAST AUTOMATED PRODUCTION OF PROPHYLACTIC CMV-SPECIFIC CTLs AFTER ALLOGENEIC HSCT.

Transplantation and cellular therapy·2026

Same author

Effectiveness and safety of primary thromboprophylaxis in antiphospholipid antibody carriers by serological 2023 ACR/EULAR domains.

Seminars in arthritis and rheumatism·2026

Same author

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

HemaSphere·2026

Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026

Same author

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Blood·2026

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients.

Mercedes Colorado¹, Mª Aranzazu Bermúdez², Carmen Montes¹

¹Hematology Department, University Hospital Marqués de Valdecilla (IDIVAL), Santander, Spain.

Clinical Lymphoma, Myeloma & Leukemia

|February 19, 2026

Summary

FLAG-IDA LITE offers a reduced-intensity option for acute myeloid leukemia (AML) in older patients. While overall outcomes were modest, achieving remission with FLAG-IDA LITE significantly improved survival for AML patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Jul 8, 2026

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells

Published on: July 12, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Area of Science:

Hematology
Oncology
Clinical Trials

Background:

Treatment of acute myeloid leukemia (AML) in elderly or medically unfit patients is challenging.
Low-intensity regimens are standard, but intermediate-intensity approaches may benefit selected patients.
FLAG-IDA LITE is a reduced-intensity fludarabine- and cytarabine-based induction regimen designed for improved tolerability.

Purpose of the Study:

To evaluate the efficacy and safety of the FLAG-IDA LITE regimen in elderly or unfit patients with AML.
To assess response rates, overall survival, and the impact of cytogenetic risk.

Main Methods:

Retrospective analysis of 91 elderly or unfit AML patients treated with FLAG-IDA LITE.
Response assessment using Cheson criteria.
Cytogenetic risk classification using 2010 MRC criteria.
Overall survival calculated from treatment initiation.

Main Results:

57% of patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi).
Median overall survival (OS) was 7 months for the cohort.
Patients achieving CR/CRi had significantly longer OS (19 months) compared to non-responders (4 months).
Adverse-risk cytogenetics correlated with lower response rates and survival.

Conclusions:

FLAG-IDA LITE demonstrated modest outcomes in a vulnerable AML population.
The regimen provided a meaningful survival benefit for patients who achieved remission.
Findings support a selective role for intermediate-intensity induction in carefully selected elderly/unfit AML patients requiring rapid disease control.